### HUMAN CANCER BIOLOGY

**Key Role of Phosphoinositide 3-Kinase Class IB in Pancreatic Cancer**
Charlotte E. Edling, Federico Selvaggi, Richard Buus, Tania Maffucci, Pierluigi Di Sebastiano, Helmut Friess, Paolo Innocenti, Hemant M. Kocher, and Marco Falasca

### CANCER THERAPY: PRECLINICAL

**Pharmacokinetic/Pharmacodynamic Modeling Identifies SN30000 and SN29751 as Tirapazamine Analogues with Improved Tissue Penetration and Hypoxic Cell Killing in Tumors**
Kevin O. Hicks, Bronwyn G. Siim, Jagdish K. Jaiswal, Frederik B. Pruijn, Annie M. Fraser, Rita Patel, Alison Hogg, H.D. Sarah Liyanage, Mary Jo Dorie, J. Martin Brown, William A. Denny, Michael P. Hay, and William R. Wilson

**Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors**
Roberta Frapolli, Elena Tamborini, Emanuela Virdis, Ezia Bello, Eva Tarantino, Sergio Marchini, Federica Grosso, Roberta Sanfillipo, Alessandro Gronchi, Juan Carlos Terzoro, Gabriella Peloso, Paolo Casali, Silvana Pilotti, and Maurizio D’Incalci

**Radiation-Guided Drug Delivery to Mouse Models of Lung Cancer**
Ghazal Hariri, Heping Yan, Hailun Wang, Zhaozhong Han, and Dennis E. Hallahan

**A Proteasome Inhibitor, Bortezomib, Inhibits Breast Cancer Growth and Reduces Osteolysis by Downregulating Metastatic Genes**
Marcy D. Jones, Julie C. Liu, Thomas K. Barthel, Sadiq Hussain, Erik Lovria, Dengfeng Cheng, Jesse A. Schoonmaker, Sudhanshu Mulay, David C. Ayers, Mary L. Bousssein, Gary S. Stein, Siddhartha Mukherjee, and Jane B. Lian
5048  Gene Expression Analysis Identifies Potential Biomarkers of Neurofibromatosis Type 1 Including Adrenomedullin

5058  Phase I Study of NK012, a Novel SN-38–Incorporating Micellar Nanoparticle, in Adult Patients with Solid Tumors
Tetsuya Hamaguchi, Toshihiko Doi, Takako Eguchi-Nakajima, Ken Kato, Yasuhide Yamada, Yasuhiro Shimada, Nozomu Fuse, Atsushi Ohtsu, Shin-ichi Matsumoto, Masaya Takanashi, and Yasuhiro Matsumura

5067  Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients

5079  A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study
Sagar Lonial, Jonathan Kaufman, Mourad Tighiouart, Ajay Nooka, Amelia A. Langston, Leonard T. Heffner, Claire Torre, Stephanie McMillan, Heather Renfroe, R. Donald Harvey, Mary J. Lechowicz, H. Jean Khoury, Christopher R. Flowers, and Edmund K. Waller

5087  Correction: Effect of Low-Dose Tamoxifen on Steroid Receptor Coactivator 3/Amplified in Breast Cancer 1 in Normal and Malignant Human Breast Tissue
Chang-Qi Zhu, Dan Strumpf, Chun-Yan Li, Qing Li, Ni Liu, Sandy Der, Frances A. Shepherd, Ming-Sound Tsao, and Igor Jurisica

IMAGING, DIAGNOSIS, PROGNOSIS

5011  Portable Filter-Based Microdevice for Detection and Characterization of Circulating Tumor Cells

5019  No Evidence of Sex-Related Survival Disparities among Head and Neck Cancer Patients Receiving Similar Multidisciplinary Care: A Matched-Pair Analysis
Jess C. Roberts, Guojun Li, Lorraine R. Reitzel, Qingyi Wei, and Erich M. Sturgis

5028  Pancreatic Cancer Screening in a Prospective Cohort of High-Risk Patients: A Comprehensive Strategy of Imaging and Genetics
Elizabeth C. Verna, Caroline Hwang, Peter D. Stevens, Heidrun Rotterdam, Stavros N. Stavropoulos, Carolyn D. Sy, Martin A. Prince, Wendy K. Chung, Robert L. Fine, John A. Chabot, and Harold Frucht

5038  Prognostic Gene Expression Signature for Squamous Cell Carcinoma of Lung
Chang-Qi Zhu, Dan Strumpf, Chun-Yan Li, Qing Li, Ni Liu, Sandy Der, Frances A. Shepherd, Ming-Sound Tsao, and Igor Jurisica

CORRECTION

Correction: Effect of Low-Dose Tamoxifen on Steroid Receptor Coactivator 3/Amplified in Breast Cancer 1 in Normal and Malignant Human Breast Tissue
Chang-Qi Zhu, Dan Strumpf, Chun-Yan Li, Qing Li, Ni Liu, Sandy Der, Frances A. Shepherd, Ming-Sound Tsao, and Igor Jurisica
ABOUT THE COVER

A humanized, monoclonal antibody against PDGFRα was able to inhibit both early colonization of the bone and late progression of skeletal lesions in a murine model of prostate cancer metastasis. The image shows a metastatic tumor produced in the proximal femur by green fluorescent PC3-ML cells, four weeks after being inoculated via the hematogenous route. For further details, please see the article by Russell and colleagues on page 5002 of this issue.